AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2903876 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (25 mg)
Number of subjects: 33
Study 31042283 — intervention group
Group type: COMPARATOR
Intervention: Artery-first procedure
Number of subjects: 86
Study 31042283 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein-first procedure
Number of subjects: 86
Study 28371687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of T2DM
Number of subjects: 1137
Study 28371687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of prediabetes
Number of subjects: 1137
Study 28371687 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for T2DM
Number of subjects: 1137
Study 28371687 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for prediabetes
Number of subjects: 1137
Study 26728914 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical female students
Number of subjects: 480
Study 26728914 — intervention group
Group type: COMPARATOR
Intervention: Non-medical female students
Number of subjects: 480
Study 26728914 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoker students
Number of subjects: 480
Study 23321547 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily
Number of subjects: 435
Study 23321547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study 23321547 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (post-hoc analysis)
Number of subjects: 435
Study 23321547 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (RPSFT analysis)
Number of subjects: 435
Study 21596247 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic Acrysof IOL
Number of subjects: 68
Study 21596247 — intervention group
Group type: COMPARATOR
Intervention: Hydrophilic C‐flex IOL (hydrophilic group C)
Number of subjects: 68
Study 21596247 — intervention group
Group type: COMPARATOR
Intervention: Hydrophilic Akreos Adapt IOL (hydrophilic group A)
Number of subjects: 68
Study 19627681 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention including manual therapy, exercises, and psychological strategies, tailored individually with a maximum of six treatments over an 8-week period.
Number of subjects: 300
Study 17122240 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating catheters
Number of subjects: 41
Study 17122240 — intervention group
Group type: COMPARATOR
Intervention: Nonstimulating catheters
Number of subjects: 41
Study 14720242 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupoint acupressure
Number of subjects: 44
Study 14720242 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 44
Study 11399822 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-reduced RBCs
Number of subjects: 520
Study 11399822 — intervention group
Group type: COMPARATOR
Intervention: Non-WBC-reduced RBCs
Number of subjects: 520
Study 9005881 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldrich formulas for predicting final QRS MI size
Number of subjects: 529
Study 9005881 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulas using ST-segment deviation, Q wave, and T wave information
Number of subjects: 529
Study 8119472 — intervention group
Group type: EXPERIMENTAL
Intervention: Bologna procedure (B)
Number of subjects: 100
Study 8119472 — intervention group
Group type: COMPARATOR
Intervention: Ingelman-Sundberg procedure (IS)
Number of subjects: 100
Study 3518072 — intervention group
Group type: EXPERIMENTAL
Intervention: dezocine 10 mg
Number of subjects: 157
Study 3518072 — intervention group
Group type: EXPERIMENTAL
Intervention: dezocine 15 mg
Number of subjects: 157
Study 3518072 — intervention group
Group type: EXPERIMENTAL
Intervention: butorphanol 2 mg
Number of subjects: 157
Study 3518072 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 157
Study 28639229 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAA4549A (400, 1200, or 3600 mg)
Number of subjects: 60
Study 28639229 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir (75 mg twice daily from days 7 to 11)
Number of subjects: 60
Study 28639229 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAA4549A
Number of subjects: 60
Study 27632919 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription omega-3 acid ethyl esters (O3AEE) 1 g/d
Number of subjects: 461
Study 27632919 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 461
Study 24254537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 52
Study 24254537 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial maze (LAM)
Number of subjects: 52
Study 24254537 — intervention group
Group type: COMPARATOR
Intervention: Control (PVI)
Number of subjects: 52
Study 22349588 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise strategy (strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers)
Number of subjects: 102
Study 22349588 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise strategy
Number of subjects: 102
Study 22349588 — intervention group
Group type: COMPARATOR
Intervention: Control exercise programme (unspecific movement exercises for the neck and shoulder)
Number of subjects: 102
Study 22349588 — intervention group
Group type: COMPARATOR
Intervention: Control exercise programme
Number of subjects: 102
Study 21524017 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept mapping teaching
Number of subjects: 0
Study 21524017 — intervention group
Group type: COMPARATOR
Intervention: Traditional lectures (Control)
Number of subjects: 0
Study 18194489 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucose tolerance test (IVGTT)
Number of subjects: 108
Study 18194489 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 108
Study 17323547 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral intake of 10% glucose solution with minerals (Group B)
Number of subjects: 0
Study 17323547 — intervention group
Group type: EXPERIMENTAL
Intervention: Special drink consisting of sugars (mainly maltodextrin) mixed with minerals (Group C)
Number of subjects: 0
Study 17323547 — intervention group
Group type: COMPARATOR
Intervention: Starvation from midnight (Group A)
Number of subjects: 0
Study 12673731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, vincristine, and fluorouracil (n = 20 patients)
Number of subjects: 46
Study 12673731 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and continuous-infusion doxorubicin (n = 26 patients)
Number of subjects: 46
Study 12673731 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 46
Study 12673731 — intervention group
Group type: EXPERIMENTAL
Intervention: FL-HCC vs typical HCC
Number of subjects: 46
Study 12673731 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced-stage disease
Number of subjects: 46
Study 12673731 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to treatment
Number of subjects: 46
Study 10922234 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNFR1 and sTNFR2 levels in ELF samples from allergic subjects during midseason in high-pollen-count period
Number of subjects: 22
Study 10922234 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNFR1 and sTNFR2 levels in ELF samples from allergic subjects during midseason in low-pollen-count period
Number of subjects: 22
Study 10922234 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNFR1 and sTNFR2 levels in ELF samples from allergic subjects in high-pollen-count period
Number of subjects: 22
Study 10922234 — intervention group
Group type: COMPARATOR
Intervention: sTNFR1 and sTNFR2 levels in ELF samples from healthy subjects
Number of subjects: 22
Study 8679045 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA) with antiemetic prophylaxis (2.5 mg DHBP)
Number of subjects: 0
Study 8679045 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA) without antiemetic prophylaxis
Number of subjects: 0
Study 8679045 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced Anaesthesia with antiemetic prophylaxis (2.5 mg DHBP)
Number of subjects: 0
Study 8679045 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced Anaesthesia without antiemetic prophylaxis
Number of subjects: 0
Study 8679045 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA) with DHBP
Number of subjects: 0
Study 8679045 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced Anaesthesia with DHBP
Number of subjects: 0
Study 8679045 — intervention group
Group type: EXPERIMENTAL
Intervention: Total rate of postoperative complications (intraocular bleedings)
Number of subjects: 0
Study 8679045 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure in TIVA groups
Number of subjects: 0
Study 8679045 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure in balanced anaesthesia groups
Number of subjects: 0
Study 1506791 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 56
Study 1506791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 6369557 — intervention group
Group type: EXPERIMENTAL
Intervention: mebendazole 500 mg thrice daily for 21 days
Number of subjects: 0
Study 6369557 — intervention group
Group type: EXPERIMENTAL
Intervention: mebendazole 500 mg thrice daily + levamisole hydrochloride 2.5 mg/kg weekly for 3 weeks
Number of subjects: 0
Study 31591650 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mg/d lactolycopene for 12 weeks
Number of subjects: 60
Study 31591650 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study 31562797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (1 mg/kg and 3 mg/kg respectively every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks)
Number of subjects: 0
Study 31562797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks) plus ipilimumab-matched placebo
Number of subjects: 0
Study 31562797 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab (3 mg/kg every 3 weeks for four doses) plus nivolumab-matched placebo
Number of subjects: 0
Study 27362401 — intervention group
Group type: EXPERIMENTAL
Intervention: Local allergen extracts
Number of subjects: 0
Study 27362401 — intervention group
Group type: COMPARATOR
Intervention: Imported allergen extracts
Number of subjects: 0
Study 27362401 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) results
Number of subjects: 0
Study 27362401 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE (sIgE) levels
Number of subjects: 0
Study 25344520 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma P. falciparum DNA concentrations
Number of subjects: 435
Study 25344520 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma P. falciparum DNA concentrations plus plasma P. falciparum HRP2 concentrations
Number of subjects: 435
Study 25344520 — intervention group
Group type: COMPARATOR
Intervention: Plasma P. falciparum HRP2 concentrations alone
Number of subjects: 435
Study 25344520 — intervention group
Group type: COMPARATOR
Intervention: Parasite densities
Number of subjects: 435
Study 24383478 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin IV 150 mg
Number of subjects: 15
Study 24383478 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine IV 0.05 mg/kg BW
Number of subjects: 15
Study 24383478 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study 21942234 — intervention group
Group type: COMPARATOR
Intervention: Indirect conventional crowns retained by glass fiber posts (Group GC)
Number of subjects: 20
Study 21942234 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrowns (Group GE)
Number of subjects: 20
Study 20071898 — intervention group
Group type: EXPERIMENTAL
Intervention: Core competency support program
Number of subjects: 56
Study 17539713 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice
Number of subjects: 36
Study 17539713 — intervention group
Group type: COMPARATOR
Intervention: No dentifrice
Number of subjects: 36
Study 15031275 — intervention group
Group type: EXPERIMENTAL
Intervention: Introductory postcard sent
Number of subjects: 348
Study 15031275 — intervention group
Group type: COMPARATOR
Intervention: No introductory postcard sent
Number of subjects: 348
Study 11536417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep therapy programme (six-session group programme including stimulus control therapy, relaxation training, and other strategies)
Number of subjects: 12
Study 11536417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep therapy programme
Number of subjects: 12
Study 9604143 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg KW-4679 (single-dose trial)
Number of subjects: 0
Study 9604143 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg KW-4679 (multiple-dose trial)
Number of subjects: 0
Study 8027959 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 24
Study 8027959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 24
Study 8027959 — intervention group
Group type: EXPERIMENTAL
Intervention: Social stress
Number of subjects: 24
Study 8027959 — intervention group
Group type: COMPARATOR
Intervention: Degree of neurological impairment, specific neurological symptoms, disability or handicap
Number of subjects: 24
Study 3421805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline hydrochloride
Number of subjects: 60
Study 3421805 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 60
Study 3421805 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 31413313 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and mTOR inhibitor (second-line treatment)
Number of subjects: 42
Study 31413313 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and mTOR inhibitor (third-line treatment)
Number of subjects: 42
Study 30920339 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline (500 mg) and galantamine (16 mg)
Number of subjects: 30
Study 30920339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28753920 — intervention group
Group type: EXPERIMENTAL
Intervention: Otto the Auto website
Number of subjects: 69
Study 28753920 — intervention group
Group type: COMPARATOR
Intervention: Control website
Number of subjects: 69
Study 28753920 — intervention group
Group type: EXPERIMENTAL
Intervention: Otto the Auto website with parental engagement
Number of subjects: 69
Study 25135348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose-insulin-potassium (GIK) therapy
Number of subjects: 0
Study 24568002 — intervention group
Group type: EXPERIMENTAL
Intervention: Beech Brook Therapy Assessment Instrument
Number of subjects: 6
Study 21467230 — intervention group
Group type: EXPERIMENTAL
Intervention: Total NNAL in urine
Number of subjects: 79
Study 21467230 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nicotine in urine
Number of subjects: 79
Study 21467230 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cotinine in urine
Number of subjects: 79
Study 21467230 — intervention group
Group type: EXPERIMENTAL
Intervention: iso-NNAL in urine
Number of subjects: 79
Study 21467230 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure levels
Number of subjects: 79
Study 21467230 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic comparison
Number of subjects: 79
Study 17530154 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised pelvic floor muscle training (PFMT)
Number of subjects: 268
Study 17530154 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study 17157592 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% topical therapy with reduced drop-skin contact (eye 1)
Number of subjects: 2
Study 17157592 — intervention group
Group type: COMPARATOR
Intervention: Bimatoprost 0.03% topical therapy (fellow eye)
Number of subjects: 2
Study 14581436 — intervention group
Group type: COMPARATOR
Intervention: Intravesical instillations of mitomycin C (MMC) alone
Number of subjects: 83
Study 14581436 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC in combination with local microwave-induced hyperthermia
Number of subjects: 83
Study 10977126 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelfoam disc impregnated with 0.60 mg of tropicamide racemate and 1.7 mg of 1‐phenylephrine hydrochloride
Number of subjects: 20
Study 10977126 — intervention group
Group type: COMPARATOR
Intervention: Topically administered drops (phenylephrine hydrochloride 2.5% solution and tropicamide 1% solution)
Number of subjects: 20
Study 8956088 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 98
Study 8956088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 1556221 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and sleep hygiene
Number of subjects: 53
Study 1556221 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and sleep hygiene plus progressive relaxation
Number of subjects: 53
Study 1556221 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and sleep hygiene plus stimulus control
Number of subjects: 53
Study 1556221 — intervention group
Group type: COMPARATOR
Intervention: Measurement control group
Number of subjects: 53
Study 3892854 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 165
Study 3892854 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 165
Study 30591320 — intervention group
Group type: EXPERIMENTAL
Intervention: TY 4mg
Number of subjects: 220
Study 30591320 — intervention group
Group type: EXPERIMENTAL
Intervention: TY 8mg
Number of subjects: 220
Study 30591320 — intervention group
Group type: COMPARATOR
Intervention: BO 2.5mg
Number of subjects: 220
Study 30591320 — intervention group
Group type: COMPARATOR
Intervention: BO 5mg
Number of subjects: 220
Study 28327140 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313
Study 28327140 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313
Study 28327140 — intervention group
Group type: COMPARATOR
Intervention: Canagliflozin
Number of subjects: 2313
Study 27701496 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching with 35% hydrogen peroxide and different light activation protocols
Number of subjects: 40
Study 27701496 — intervention group
Group type: COMPARATOR
Intervention: In-office bleaching with 35% hydrogen peroxide
Number of subjects: 40
Study 24067879 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine (600 mg/d)
Number of subjects: 0
Study 23115407 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 consecutive 10.7-h night shifts
Number of subjects: 29
Study 23115407 — intervention group
Group type: COMPARATOR
Intervention: 3 consecutive days off duty
Number of subjects: 29
Study 19933245 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD
Number of subjects: 189
Study 19933245 — intervention group
Group type: COMPARATOR
Intervention: Classroom-based instruction
Number of subjects: 189
Study 19933245 — intervention group
Group type: EXPERIMENTAL
Intervention: Class plus DVD
Number of subjects: 189
Study 16741368 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (once daily SLIT) with 10 days updosing (T1), 20 days maintenance treatment (T2), and 2 consecutive months on maintenance treatment (T3 and T4)
Number of subjects: 135
Study 16741368 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with placebo updosing (T1), placebo maintenance (T2), initiated active treatment at T3, and continued active treatment until the end of the study (T4)
Number of subjects: 135
Study 16741368 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (once daily SLIT)
Number of subjects: 135
Study 16741368 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 135
Study 14703417 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (loading dose of 2 x 10(6) KIU followed by continuous infusion of 0.5 x 10(6) KIU/h)
Number of subjects: 24
Study 14703417 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 24
Study 10892227 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention problems
Number of subjects: 387
Study 10892227 — intervention group
Group type: EXPERIMENTAL
Intervention: Inattentive first graders with normal reading scores after kindergarten
Number of subjects: 387
Study 8936577 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day interactive workshop on disease prevention
Number of subjects: 34
Study 8936577 — intervention group
Group type: COMPARATOR
Intervention: Control group (no workshop)
Number of subjects: 34
Study 1555479 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase and subcutaneous heparin
Number of subjects: 40000
Study 1555479 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase and intravenous heparin
Number of subjects: 40000
Study 1555479 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-loaded, weight-adjusted rt-PA and intravenous heparin
Number of subjects: 40000
Study 1555479 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of streptokinase and rt-PA and intravenous heparin
Number of subjects: 40000
Study 3921279 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (60 mg/24 hr)
Number of subjects: 15
Study 3921279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31007691 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet
Number of subjects: 114
Study 31007691 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (fish oil) 1500 mg/d
Number of subjects: 114
Study 31007691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 28811095 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinitas Soothe
Number of subjects: 50
Study 28811095 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyabak
Number of subjects: 50
Study 28811095 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraTears
Number of subjects: 50
Study 28811095 — intervention group
Group type: EXPERIMENTAL
Intervention: Tears Again
Number of subjects: 50
Study 26636393 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional extracorporeal circulation (CECC)
Number of subjects: 120